Cytokinetic Study of MCF-7 Cells Treated with Commercial and Recombinant Bromelain

  • Fouz, Nour (Bioprocess and Molecular Engineering Research Unit, International Islamic University Malaysia) ;
  • Amid, Azura (Bioprocess and Molecular Engineering Research Unit, International Islamic University Malaysia) ;
  • Hashim, Yumi Zuhanis Has-Yun (Bioprocess and Molecular Engineering Research Unit, International Islamic University Malaysia)
  • Published : 2013.11.30


Background: Breast cancer is a leading cause of death in women. The available chemotherapy drugs have been associated with many side effects. Bromelain has novel medicinal qualities including anti-inflammatory, anti-thrombotic, fibrinolytic and anti-cancer functions. Commercially available bromelain is obtained through tedious methods; therefore, recombinant bromelain may provide a cheaper and simpler choice with similar quality. Materials and Methods: This study aimed to assess the effects of commercial and recombinant bromelain on the cytokinetic behavior of MCF-7 breast cancer cells and their potential as therapeutic alternatives in cancer treatment. Cytotoxic activities of commercial and recombinant bromelain were determined using (sulforhodamine) SRB assay. Next, cell viability assays were conducted to determine effects of commercial and recombinant bromelain on MCF-7 cell cytokinetic behavior. Finally, the established growth kinetic data were used to modify a model that predicts the effects of commercial and recombinant bromelain on MCF-7 cells. Results: Commercial and recombinant bromelain exerted strong effects towards decreasing the cell viability of MCF-7 cells with $IC_{50}$ values of 5.13 ${\mu}g/mL$ and 6.25 ${\mu}g/mL$, respectively, compared to taxol with an $IC_{50}$ value of 0.063 ${\mu}g/mL$. The present results indicate that commercial and recombinant bromelain both have anti-proliferative activity, reduced the number of cell generations from 3.92 to 2.81 for commercial bromelain and to 2.86 for recombinant bromelain, while with taxol reduction was to 3.12. Microscopic observation of bromelain-treated MCF-7 cells demonstrated detachment. Inhibition activity was verified with growth rates decreased dynamically from 0.009 $h^{-1}$ to 0.0059 $h^{-1}$ for commercial bromelain and to 0.0063 $h^{-1}$ for recombinant bromelain. Conclusions: Commercial and recombinant bromelain both affect cytokinetics of MCF-7 cells by decreasing cell viability, demonstrating similar strength to taxol.


Bromelain;cell viability;growth kinetics;MCF-7 cells;recombinant


  1. Afenya EK, Calderon CP (2000). Diverse ideas on the growth kinetics of disseminated cancer cells. Bull Math Biol, 62, 527-42.
  2. Amid A, Ismail NA, Yusof F, Salleh HM (2011). Expression, purification, and characterization of a recombinant stem bromelain from ananas comosus. Process Biochem, 46, 2232-9.
  3. Bajzer Z (1999). Gompertzian growth as a self-similar and allometric process. Growth Dev Aging, 63, 3-11.
  4. Bala M, Salleh HM, Amid A, et al (2011). Recovery of recombinant bromelain from escherichia coli bl21-ai. Afr J Biotechnol, 10, 18829-32.
  5. Castell JV (1995). Intestinal absorption of undegraded bromelain in humans, (Berlin: Springer Berlin Heidelberg).
  6. Chik WDW, Amid A, and Jamal P (2010). Purification and cytotoxicity assay of tomato (lycopersicon esculen tum) leaves methanol extract as potential anticancer agent. J App Sci, 10, 3283-8.
  7. Chobotova K, Vernallis AB, Majid FA (2010). Bromelain's activity and potential as an anti-cancer agent: Current evidence and perspectives. Cancer Lett, 290, 148-56.
  8. Dang C, Gilewski TA, Surbone A, Norton L (2003). Cytokinetics, (Rockville Pike: BC Decker Inc).
  9. Deasy BM, Jankowski RJ, Payne TR, et al (2003). Modeling stem cell population growth: Incorporating terms for proliferative heterogeneity. Stem Cells, 21, 536-45.
  10. Desantis C, Melissa M, Rebecca S, Ahmedin J (2009). Breast cancer facts and figures 2009-2010. In, (Atlanta, Georgia.: American Cancer Society, Inc.), pp. 1-38.
  11. Freshney RI (2010). Culture of animal cells: A manual of basic technique and specialized application, 6th edn (Canada: John WIley & Sons, Inc.).
  12. Gwyther SJ, Schwartz LH (2008). How to assess anti-tumour efficacy by imaging techniques. Eur J Cancer, 44, 39-45.
  13. Hale LP, Greer PK, Trinh CT, Gottfried MR (2005a). Treatment with oral bromelain decreases colonic inflammation in the il-10-deficient murine model of inflammatory bowel disease. Clin Immunol, 116, 135-42.
  14. Hale LP, Greer PK, Trinh CT, James CL (2005b). Proteinase activity and stability of natural bromelain preparations. Int Immunopharmacol, 5, 783-93.
  15. Iwata K, Kawasaki K, Shigesada N (2000). A dynamical model for the growth and size distribution of multiple metastatic tumors. J Theor Biol, 203, 177-86.
  16. Koblinski JE, Ahram M, Sloane BF (2000). Unraveling the role of proteases in cancer. Clin Chim Acta, 291, 113-35.
  17. Lednicer D, Narayanan VL (1993). Acquisation and screening of natural products as potential anticancer and aids antiviral agents, (Boca Raton: CRC Press, Inc.).
  18. Manhart N, Akomeah R, Bergmeister H, et al (2002). Administration of proteolytic enzymes bromelain and trypsin diminish the number of cd4+ cells and the interferon-gamma response in peyer’s patches and spleen in endotoxemic balb/c mice. Cell Immunol, 215, 113-9.
  19. Maurer HR (2001). Bromelain: Biochemistry, pharmacology and medical use. Cell Mol Life Sci, 58, 1234-45.
  20. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P (2007). Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res, 67, 3970-5.
  21. Michaelis LC, Ratain MJ (2006). Measuring response in a post-recist world: From black and white to shades of grey. Nat Rev Cancer, 6, 409-14.
  22. Mosley CA, Liotta DC, Snyder JP (2007). Highly active anticancer curcumin analogues. Adv Exp Med Biol, 595, 77-103.
  23. O’Reilly MS, Boehm T, Shing Y, et al (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85.
  24. Saville MW, Lietzau J, Pluda JM et al (1995). Treatment of hiv-associated kaposi's sarcoma with paclitaxel. Lancet, 346, 26-8.
  25. Society AC (2013). Cancer prevention and early detection facts and figures 2013. In, (Atlanta: AMerican Cancer Society).
  26. Tysnes BB, Maurer HR, Porwol T, et al (2001). Bromelain reversibly inhibits invasive properties of glioma cells. Neoplasia, 3, 469-79.
  27. Zavadova E, Desser L, Mohr T (1995). Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biother, 10, 147-52.

Cited by

  1. vol.33, pp.1, 2016,